Cytokinetics (NASDAQ:CYTK) CEO Sells $584,400.00 in Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) CEO Robert Blum sold 7,500 shares of the business’s stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $77.92, for a total value of $584,400.00. Following the completion of the sale, the chief executive officer owned 400,330 shares in the company, valued at $31,193,713.60. This represents a 1.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Cytokinetics Stock Up 1.8%

Cytokinetics stock traded up $1.42 during midday trading on Thursday, reaching $78.64. The stock had a trading volume of 2,348,837 shares, compared to its average volume of 2,243,325. Cytokinetics, Incorporated has a 12 month low of $29.31 and a 12 month high of $80.20. The firm’s 50-day moving average price is $65.30 and its 200 day moving average price is $64.38. The firm has a market capitalization of $9.79 billion, a PE ratio of -11.50 and a beta of 0.38.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($1.67) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($1.67). The firm had revenue of $19.36 million during the quarter, compared to the consensus estimate of $8.52 million. During the same quarter in the prior year, the firm posted ($1.36) earnings per share. The company’s revenue was up 1112.5% on a year-over-year basis. Equities research analysts expect that Cytokinetics, Incorporated will post -6.31 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Royal Bank Of Canada lifted their target price on Cytokinetics from $101.00 to $119.00 and gave the company an “outperform” rating in a report on Wednesday, May 6th. Needham & Company LLC lifted their target price on Cytokinetics from $85.00 to $102.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. B. Riley Financial lifted their target price on Cytokinetics from $90.00 to $108.00 and gave the company a “buy” rating in a report on Wednesday, January 21st. Stifel Nicolaus lifted their target price on Cytokinetics from $98.00 to $108.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Finally, Morgan Stanley lifted their target price on Cytokinetics from $90.00 to $103.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.55.

Key Stories Impacting Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: HC Wainwright raised its 2026 EPS estimates for Cytokinetics and reaffirmed a Buy rating with a $140 price target, signaling confidence in the company’s longer-term growth outlook. HC Wainwright estimate updates
• Positive Sentiment: HC Wainwright also lifted its Q2, Q3, and Q4 2026 EPS estimates, and improved its FY2026 forecast, suggesting slightly better near-term earnings expectations for the biopharma company. HC Wainwright estimate updates
• Positive Sentiment: JPMorgan reportedly assigned a new $97 price target on CYTK, adding to the recent analyst-driven interest that may be helping sentiment. JPMorgan price target article
• Neutral Sentiment: The company announced it will host its third annual CLIMB muscle biology research symposium on May 29, a visibility-building event that is more informational than immediately financial. CLIMB symposium announcement
• Neutral Sentiment: Options trading was reported as unusually high, which can indicate heightened investor speculation around the stock, but it does not by itself confirm a fundamental catalyst. Unusually high options trading article
• Negative Sentiment: Some of HC Wainwright’s longer-term EPS estimates were revised lower, including FY2027 and FY2028, which could temper enthusiasm about profitability over time. HC Wainwright estimate updates

Institutional Trading of Cytokinetics

A number of large investors have recently modified their holdings of the business. Bank of Montreal Can boosted its position in shares of Cytokinetics by 1.2% during the 4th quarter. Bank of Montreal Can now owns 13,292 shares of the biopharmaceutical company’s stock valued at $845,000 after acquiring an additional 160 shares during the last quarter. Kennedy Capital Management LLC boosted its position in shares of Cytokinetics by 1.2% during the 4th quarter. Kennedy Capital Management LLC now owns 13,183 shares of the biopharmaceutical company’s stock valued at $838,000 after acquiring an additional 162 shares during the last quarter. UMB Bank n.a. boosted its position in shares of Cytokinetics by 10.6% during the 3rd quarter. UMB Bank n.a. now owns 1,762 shares of the biopharmaceutical company’s stock valued at $97,000 after acquiring an additional 169 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in shares of Cytokinetics by 46.0% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 543 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 171 shares during the last quarter. Finally, Vident Advisory LLC boosted its position in shares of Cytokinetics by 1.4% during the 4th quarter. Vident Advisory LLC now owns 16,455 shares of the biopharmaceutical company’s stock valued at $1,046,000 after acquiring an additional 234 shares during the last quarter.

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.